Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
BioArctic AB said its partner Eisai reported preliminary Q2 2026 global Leqembi sales of JPY 29.3 billion. BioArctic’s royalty is SEK 179 million, about 10% higher than in Q2 2025. Excluding a Q2 2025 China stockpiling effect of about JPY 5.3 billion, royalty revenues rose about 43% year over year. BioArctic’s Q2 report is due Aug 26, 2026.
How this was made
The 30-second read
Why it matters
The disclosed Q2 2026 sales and royalty amount update BioArctic’s royalty outlook and reduce uncertainty ahead of its Aug 26 Q2 report.
Market read
Concrete Q2 sales and royalty figures provide a near-term earnings model input for BIOA’s royalty stream.
What to watch
Royalty revenue depends on sales mix and any future changes in dosing patterns, reimbursement, or competitive dynamics not detailed in this PR.
Background
BioArctic’s Leqembi commercialization is partnered with Eisai, with BioArctic entitled to sales milestones and global royalties; Eisai publishes preliminary Leqembi revenue alongside Biogen’s reporting.
Ticker impact
BioArctic discloses Leqembi Q2 2026 global sales of JPY 29.3B, implying a Q2 royalty of SEK 179M, up ~10% YoY.
Likely modest positive bias for BIOA as investors update expectations for royalty receipts tied to Leqembi demand.
The article provides a concrete Q2 sales figure and the resulting royalty amount, plus YoY growth and an adjusted growth rate excluding a China stockpiling effect.
Market effects
Reinforces demand momentum for an Alzheimer’s antibody franchise, which can support sentiment toward Alzheimer’s biopharma royalty models.
China stockpiling effect discussion highlights regional demand volatility that may affect quarterly royalty seasonality.
Global sales and royalty math provide a cross-market signal for lecanemab commercialization progress across multiple regulatory regions.
Counterpoint
The Q2 comparison includes a prior-year China stockpiling effect, so headline YoY growth may overstate underlying run-rate without continued normalization.
Key entities
- equity issuerBioArctic AB (publ)
Receives royalties on global Leqembi sales; discloses Q2 2026 royalty derived from Eisai’s preliminary revenue.
- partnerEisai
Publishes preliminary global Leqembi revenue used to calculate BioArctic’s royalty.
- productLeqembi (lecanemab)
Anti-amyloid monoclonal antibody for early Alzheimer’s; sales drive BioArctic royalties.